NeoGenomics Makes Oncology Test Ordering Available Through Epic Aura EHR Integration (ir.neogenomics.com)

• NeoGenomics oncology testing portfolio now accessible through Epic Aura.
• Integration aims to streamline ordering and speed clinical decisions.
• Company cites potential 20-30% increase in test adoption per site.
• Supports future liquid biopsy and MRD capabilities.

"NeoGenomics (NASDAQ: NEO) announced on April 23, 2026 that its full oncology testing portfolio is now accessible through Epic Aura, an EHR-based ordering platform. This integration allows physicians to order tests and view results within the Epic workflow. NeoGenomics expects it to increase test adoption per site by 20-30% and accelerate treatment decisions. The move supports its digital health strategy and future capabilities like liquid biopsy and MRD."